Ισραήλ - Εβραϊκά - Ministry of Health

abic marketing ltd, israel - apomorphine hydrochloride - תמיסה להזרקה\אינפוזיה - apomorphine hydrochloride 10 mg/ml - apomorphine - apomorphine - the treatment of disabling motor fluctuations ("on-off" phenomena) in patients with parkinson's disease which persist despite individually titrated treatment with levodopa (with a peripheral decarboxylase inhibitor) and/or other dopamine agonists.

Ισραήλ - Εβραϊκά - Ministry of Health

teva israel ltd - apomorphine hydrochloride - תמיסה להזרקה - apomorphine hydrochloride 10 mg/ml - apomorphine - apomorphine - the treatment of disabling motor fluctuations ( "on-off" phenomena) in patients with parkinson's disease which persist despite individually titrated treatment with levodopa ( with a peripheral decarboxylase inhibitor ) and/or other dopamine agonists.

Ισραήλ - Εβραϊκά - Ministry of Health

cts ltd - rotigotine 4 mg / 24 hour - patches - rotigotine - neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through the late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on-off" fluctuations).

Ισραήλ - Εβραϊκά - Ministry of Health

cts ltd - rotigotine 6 mg / 24 hour - patches - rotigotine - neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through the late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on-off" fluctuations).

Ισραήλ - Εβραϊκά - Ministry of Health

cts ltd - rotigotine 8 mg / 24 hour - patches - rotigotine - neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through the late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on-off" fluctuations).